Amicus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Amicus Therapeutics
FOLD Stock  USD 6.13  0.01  0.16%   
Amicus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Amicus Therapeutics' valuation are provided below:
Gross Profit
492.1 M
Profit Margin
(0.05)
Market Capitalization
1.9 B
Enterprise Value Revenue
3.8305
Revenue
543.1 M
There are over one hundred nineteen available fundamental signals for Amicus Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Amicus Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 3 B. The current year's Enterprise Value is expected to grow to about 3.3 B

Amicus Therapeutics Total Revenue

554.71 Million

Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9 M, Interest Expense of 52.1 M or Other Operating Expenses of 510 M, as well as many indicators such as Price To Sales Ratio of 5.16, Dividend Yield of 0.0 or PTB Ratio of 15.52. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Amicus Stock
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets469.8 M785 M579.9 M
Slightly volatile
Other Assets41.8 M48.6 M55.6 M
Very volatile
Common Stock Shares Outstanding319.6 M304.4 M173 M
Slightly volatile
Liabilities And Stockholders Equity491.9 M785 M581.3 M
Slightly volatile
Other Stockholder Equity3.1 B2.9 B1.5 B
Slightly volatile
Total Liabilities299.1 M591 M368.5 M
Slightly volatile
Other Current Liabilities114.7 M109.2 M60.8 M
Slightly volatile
Total Current Liabilities156.1 M148.7 M88.6 M
Slightly volatile
Accounts Payable10.4 M12.9 M12.5 M
Slightly volatile
Cash224.4 M213.8 M118.6 M
Slightly volatile
Short Term Investments34.4 M36.2 M150.6 M
Pretty Stable
Other Current Assets21.6 M34.9 M26 M
Slightly volatile
Common Stock3.1 M2.9 M1.8 M
Slightly volatile
Property Plant Equipment37.2 M35.4 M20 M
Slightly volatile
Short and Long Term Debt Total465.8 M443.6 M225.8 M
Slightly volatile
Other Liabilities20.2 M21.3 M78.7 M
Pretty Stable
Property Plant And Equipment Net54.2 M51.7 M30.6 M
Slightly volatile
Non Current Assets Total209.7 M280.3 M250 M
Slightly volatile
Non Currrent Assets Other7.4 M13.6 M8.7 M
Slightly volatile
Cash And Short Term Investments252.5 M249.9 M270 M
Slightly volatile
Common Stock Total Equity3.4 M3.2 M1.8 M
Slightly volatile
Non Current Liabilities Total255.5 M442.3 M290.5 M
Slightly volatile
Property Plant And Equipment Gross84.5 M80.4 M38.5 M
Slightly volatile
Total Current Assets306.8 M504.7 M334.6 M
Slightly volatile
Short Term Debt7.7 M8.5 M9.2 M
Slightly volatile
Net Receivables106.2 M101.1 M34 M
Slightly volatile
Capital Surpluse1.7 B3.1 B1.6 B
Slightly volatile
Non Current Liabilities Other6.7 M7.1 M92.8 M
Slightly volatile
Warrants71 K74.7 K6.2 M
Pretty Stable
Long Term Debt Total244.7 M450.8 M198.4 M
Slightly volatile
Long Term Investments14 M15.7 M17.1 M
Slightly volatile
Short and Long Term Debt100.3 M189.1 M103.5 M
Slightly volatile
Capital Lease Obligations46.1 M53.5 M27.7 M
Slightly volatile
Net Invested Capital482.7 M584.2 M558.1 M
Slightly volatile
Net Working Capital303.5 M356 M349.5 M
Pretty Stable
Capital Stock2.9 M2.9 M2.3 M
Slightly volatile

Amicus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9 M8.5 M4.4 M
Slightly volatile
Other Operating Expenses510 M485.7 M296.8 M
Slightly volatile
Research Development120.4 M109.4 M145.2 M
Slightly volatile
Total Operating Expenses473 M450.5 M280.2 M
Slightly volatile
Selling General Administrative339.5 M323.4 M129.9 M
Slightly volatile
Cost Of Revenue55.6 M52.9 M23.8 M
Slightly volatile
Interest Income5.1 M5.4 M3.4 M
Slightly volatile
Reconciled Depreciation6.7 M8.5 M5 M
Slightly volatile
Extraordinary Items85.5 K90 K1.4 M
Slightly volatile

Amicus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures4.2 M3.6 M4.7 M
Slightly volatile
End Period Cash Flow227.6 M216.7 M120.3 M
Slightly volatile
Begin Period Cash Flow262.6 M250.1 M110.9 M
Slightly volatile
Depreciation9 M8.5 M4.4 M
Slightly volatile
Stock Based Compensation89.2 M84.9 M37.4 M
Slightly volatile
Change To Netincome61.4 M89.2 M56.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.165.427484.7821
Slightly volatile
Days Sales Outstanding66.3669.8495142
Pretty Stable
Stock Based Compensation To Revenue0.150.16072.102
Slightly volatile
Capex To Depreciation0.390.41571.4626
Slightly volatile
EV To Sales5.575.862677.4374
Slightly volatile
Inventory Turnover0.420.44570.7701
Slightly volatile
Days Of Inventory On Hand532819867
Slightly volatile
Payables Turnover2.984.08923.4328
Slightly volatile
Sales General And Administrative To Revenue1.191.257.526
Slightly volatile
Research And Ddevelopement To Revenue0.20.20714.471
Slightly volatile
Capex To Revenue0.00640.00670.3472
Slightly volatile
Cash Per Share0.780.82125.3449
Slightly volatile
Days Payables Outstanding84.889.2593892
Pretty Stable
Income Quality1.080.60410.7847
Slightly volatile
Intangibles To Total Assets0.370.27390.3299
Very volatile
Current Ratio6.563.39435.4341
Slightly volatile
Receivables Turnover3.585.22554.3237
Slightly volatile
Capex Per Share0.01110.01170.4929
Slightly volatile
Revenue Per Share1.821.73560.6829
Slightly volatile
Interest Debt Per Share0.91.62051.126
Slightly volatile
Debt To Assets0.590.56510.2929
Slightly volatile
Operating Cycle933889656
Very volatile
Days Of Payables Outstanding84.889.2593892
Pretty Stable
Long Term Debt To Capitalization0.70.66780.3655
Slightly volatile
Quick Ratio2.472.59555.0557
Slightly volatile
Net Income Per E B T2.051.95111.087
Slightly volatile
Cash Ratio1.911.43751.6909
Slightly volatile
Days Of Inventory Outstanding532819867
Slightly volatile
Days Of Sales Outstanding66.3669.8495142
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.161.10481.0614
Very volatile
Fixed Asset Turnover10.7410.22624.4277
Slightly volatile
Debt Ratio0.590.56510.2929
Slightly volatile
Price Sales Ratio5.165.427484.7821
Slightly volatile
Asset Turnover0.710.6730.2422
Slightly volatile

Amicus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3 B2.9 B2 B
Slightly volatile
Enterprise Value3.3 B3.1 B2.1 B
Slightly volatile

Amicus Fundamental Market Drivers

Forward Price Earnings49.0196
Cash And Short Term Investments249.9 M

Amicus Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Amicus Therapeutics Financial Statements

Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue14.3 M9.2 M
Cost Of Revenue52.9 M55.6 M
Total Revenue528.3 M554.7 M
Stock Based Compensation To Revenue 0.16  0.15 
Sales General And Administrative To Revenue 1.25  1.19 
Research And Ddevelopement To Revenue 0.21  0.20 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.74  1.82 
Ebit Per Revenue 0.05  0.05 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
How To Invest In Amicus
Details
Is Amicus Stock a good investment?
Details
What is Amicus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.09)
Revenue Per Share
1.777
Quarterly Revenue Growth
0.134
Return On Assets
0.0395
Return On Equity
(0.18)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY